The objective of this study was to estimate the excess mortality and length of hospital stay (LOS) associated with MRSA bloodstream infections (BSI) in European hospitals. Between July 2007 and June 2008, a multicenter, prospective, parallel matched-cohort study was carried out in 13 tertiary care hospitals in as many European countries. Compared to the controls, MRSA patients had higher 30-day mortality (adjusted odds ratio [aOR] =4.4) and higher hospital mortality (adjusted hazard ratio [aHR] =3.5). Their excess LOS was 9.2 days. MSSA patients also had higher 30-day (aOR =2.4) and hospital (aHR =3.1) mortality and an excess LOS of 8.6 days.
COBISS.SI-ID: 2478309
Our objectives were to determine excess mortality and length of hospital stay (LOS) attributable to bloodstream infection (BSI) caused by third-generation-cephalosporin-resistant Escherichia coli (REC) in Europe. A prospective parallel matched cohort design was used. Thirteen European tertiary care centres participated between July 2007 and June 2008. REC patients had a higher mortality at 30 days (adjusted odds ratio = 4.6) and a higher hospital mortality (adjusted hazard ratio = 5.7) than their controls. LOS was increased by 8 days. For SEC patients, these figures were adjusted odds ratio = 1.9, adjusted hazard ratio = 2.0 and excess LOS = 3 days. A 2.5 times [95% confidence interval (95% CI) 0.9–6.8] increase in all-cause mortality at 30 days and a 2.9 times (95% CI 1.2–6.9) increase in mortality during entire hospital stay as well as an excess LOS of 5 days (95% CI 0.4–10.2) could be attributed to resistance to third-generation cephalosporins in E. coli BSI.
COBISS.SI-ID: 2406117
In this paper, we combined the clinical effect estimates from the previously published E. coli and S. aureus paper, prevalence data from EARSS and a WHO cost model to come to estimates about the number of deaths, bed days and costs associated with MRSA and G3C resistant E. coli BSI.
COBISS.SI-ID: 2554341